<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230626058585N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-17</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of acupuncture on headache</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of  electroacupuncture and manual acupuncture  in patients with tension-type headache: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72759</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: However, due to the fact that we do not have any intervention in the control group, we do not have blinding. But in order to know whether electroacupuncture is superior to manual acupuncture or not, blinding will be done in the intervention groups, so that in both groups, the electrodes are connected to the needles, but in the manual acupuncture group, there is no current in wire and only the blinking diode that simulates the electric stimulus can be seen and its sound can be heard, Randomization description: Blocked
individual
 using the online site https://www.sealedenvelope.com random allocation into three groups A (electroacupuncture), group B (manual acupuncture) and group C (usual care). Randomization will be done based on Block Randomization with blocks of 6. A block size of 6 will be used for random allocation. The prepared blocks will be placed inside the envelope. According to the order of arrival of patients, one of the envelopes will be randomly selected and based on the obtained blocks, patients will be allocated to groups.
 Allocation Concealment method:
Using sealed and waxed opaque envelopes:
In this way, the envelopes will be prepared and printed by one of the team members and random numbers will be placed inside the envelope. The lid of the envelopes will be closed and its contents will not be visible from the outside. Then, first, the purpose of the study is explained to the person who meets the stated conditions, and if the person wishes, he signs the informed consent form and takes an envelope, then opens it and enters one of the three groups based on the contents of the envelope, Blinding description: 1- in order to know whether electroacupuncture is superior to manual acupuncture or not, blinding will be done in the intervention groups, so that in both groups, the electrodes are connected to the needles, but in the manual acupuncture group, there is no current in wire and only the blinking diode that simulates the electric stimulus can be seen and its sound can be heard.
2- Those who collect and analyze the information and the safety monitoring board do not know the names of the patients and the division of the groups and the assignment of each patient to each group.</study_design>
      <phase>3</phase>
      <hc_freetext>Tension-type headache.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: electroacupuncture: after disinfecting the skin, disposable sterile needles size 25 x 0.25 in points (GB20-GV20-LI4-LV3-EX HN 5-ST8-GB8-SP6-ST36-EX HN 3-SJ 5 -LU 7-ST40-REN12-PC6-HT7-BL60) with a certain depth based on the instructions of Chinese medicine ،are placed on both sides. The needles remain in place for 30 minutes. The needles are connected to the electro device in the distal points of both hands and feet and a local point and are stimulated for 30 minutes. The points that are connected to the electro include: DU 20 /EX-HN3 in head- LI4 / PC 6 in both hands - in both legs LIV 3 / SP 6. Intervention 2: The second intervention group: manual acupuncture - needles in points (GB20-GV20-LI4-LV3-EX HN 5-ST8-GB8-SP6-ST36-EX HN 3-SJ 5-LU 7-ST40-REN12-PC6-HT7- BL60) with a certain depth according to Chinese medicine instructions, will be placed on both sides and will remain in place for 30 minutes. In order to blind the electrodes, they are connected to the needles, but the passage of the electric current is interrupted and only the flashing diode that simulates the electric stimulus can be seen and its sound can be heard. Intervention 3: Control group: The participants in the usual care group continued their previous treatment without any intervention and completed the questionnaires similar to the two intervention groups. After the follow-up period, as a reward, they were treated with acupuncture with or without electro, based on the treatment result. will be placed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shirin Shafaee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Persian and Complementary medicine, Campus of Ferdowsi University, Azadi Square</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9138813944</zip>
        <telephone>+98 51 3884 8930</telephone>
        <email>shafaeish4001@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyyed Kazem Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Persian and Complementary medicine, Campus of Ferdowsi University, Azadi Square</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9138813944</zip>
        <telephone>+98 51 3884 8930</telephone>
        <email>farahmandk1@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients suffering from chronic and episodic tension headache based on the criteria of the International Headache Society (ICHD 3beta) who suffer from headache for more than one year.
 Age 18 to 65 years
 Age of onset of headache below 50 years
 Desire to participate in the study and sign an informed consent
Any headache treatment should be started at least 3 months before the study and continued without any changes (except the treatment of acute headache attack) in the last 3 months and during the intervention and follow-up period. These treatments include pain relievers when needed (such as acetaminophen and ibuprofen) and/or preventive medications (such as amitriptyline) or even non-pharmacological treatments (such as relaxation techniques).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Suffering from migraine headache for more than one day in a month
Secondary headaches related to organic disease (for example: cerebral hemorrhage, cerebral thrombosis, vascular malformation, hypertension)
Severe physical or mental illness such as seizures, coagulation disorders, heart disease, liver disease, kidney disease and other organs.
Pregnancy, breastfeeding or decision to become pregnant during the study period
Addiction to smoking, alcohol, drugs
Acupuncture treatment in the last 6 months (in order to blind the treatment method, he has never had a history of electro-acupuncture)
Continuous use of headache pain relievers more than 10 days a month for more than 3 months (Medication-overuse headache)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G44.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Tension-type headache</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: electroacupuncture: after disinfecting the skin, disposable sterile needles size 25 x 0.25 in points (GB20-GV20-LI4-LV3-EX HN 5-ST8-GB8-SP6-ST36-EX HN 3-SJ 5 -LU 7-ST40-REN12-PC6-HT7-BL60) with a certain depth based on the instructions of Chinese medicine ،are placed on both sides. The needles remain in place for 30 minutes. The needles are connected to the electro device in the distal points of both hands and feet and a local point and are stimulated for 30 minutes. The points that are connected to the electro include: DU 20 /EX-HN3 in head- LI4 / PC 6 in both hands - in both legs LIV 3 / SP 6</i_keyword>
      <i_keyword>The second intervention group: manual acupuncture - needles in points (GB20-GV20-LI4-LV3-EX HN 5-ST8-GB8-SP6-ST36-EX HN 3-SJ 5-LU 7-ST40-REN12-PC6-HT7- BL60) with a certain depth according to Chinese medicine instructions, will be placed on both sides and will remain in place for 30 minutes. In order to blind the electrodes, they are connected to the needles, but the passage of the electric current is interrupted and only the flashing diode that simulates the electric stimulus can be seen and its sound can be heard.</i_keyword>
      <i_keyword>Control group: The participants in the usual care group continued their previous treatment without any intervention and completed the questionnaires similar to the two intervention groups. After the follow-up period, as a reward, they were treated with acupuncture with or without electro, based on the treatment result. will be placed</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Average tension headache intensity over 4 weeks. Timepoint: Initially before randomization and 4, 8, 12, weeks after randomization. Method of measurement: Using a visual analog scale (VAS ) includes a straight horizontal line marked from 0-10. 0 means no pain and 10 means very severe pain. The participants are asked to Answer the question: How severe was your worst pain in the past 24 hours?, and then mark the point on the line that corresponds to the pain level.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The dosage of painkillers for acute headache attacks. Timepoint: Total dose consumed during 4 weeks (time interval: initially before randomization, 4, 8, 12 weeks after randomization). Method of measurement: The name, number and dose of acute pain reliever are recorded every day, the total dosage is checked every 4 weeks.</sec_outcome>
      <sec_outcome>Assessment of quality of life. Timepoint: At baseline before randomization, 4, 8, 12 weeks after randomization. Method of measurement: Using  a 36-item short form survey instrument (SF-36) questionnaire that is used to evaluate people's quality of life, which includes 36 questions for physical and mental health, which are divided into 0-100 scores (0 = worst health condition and 100 = best health condition). .. The average score of 50 is expressed as the normative value for all scales.</sec_outcome>
      <sec_outcome>Assessment of anxiety score. Timepoint: At baseline before randomization, 4, 8, 12 weeks after randomization. Method of measurement: Beck's anxiety questionnaire.</sec_outcome>
      <sec_outcome>Assessment of depression status. Timepoint: At baseline before randomization, 4, 8, 12 weeks after randomization. Method of measurement: Beck depression questionnaire.</sec_outcome>
      <sec_outcome>Number of headache days. Timepoint: It will be daily recorded by patients. For statistical analysis: Initially, before randomization, and 4, 8, 12 weeks after randomization. Method of measurement: Headaches lasting more than 30 minutes per day are recorded in the headache diary. The response rate is defined as a reduction of more than 50% in the number of headache days.</sec_outcome>
      <sec_outcome>Duration of pain attacks. Timepoint: Every day, the hours that the patient had a headache are recorded. for statistical analysis: Initially before randomization and 4, 8, 12, weeks after randomization. Method of measurement: By recording the start and end time of the headache in the diary, the total pain hours in 4 weeks will be calculated.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-09</approval_date>
        <contact_name>Ethics committee of mashhad university of medical sciences</contact_name>
        <contact_address>Building number one of Mashhad University of Medical Sciences (Qureshi), in front of University 18, Daneshgah St. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
